10.02.20
8 min. Read

Proteus founders explain. Investors talk DTx.

Issue 072.

Get E&O weekly. | Subscribe

Digital health research from Brian Dolan.

Welcome to E&O.

Last week I published The Virgin Pulse Report. Thanks to everyone who sent in feedback. Here's what's happening this week:

  • I am working my way through some long write-ups of the DTx East event, which took place virtually in September. The first of a few quasi-transcripts of discussions at the event

Paying Subscribers Only

It's a good one, too.
This digital health research is for paying Exits & Outcomes subscribers only. Subscribe now to read this article, get the weekly newsletter, and receive unrestricted access to past and future research from the Exits & Outcomes archives. Smash the link above or below to subscribe yourself -- or head over to our pricing page to subscribe your team or your whole company!
×

Full access to E&O's research and newsletters.

Get the subscribers-only newsletters + research reports + databases
Help me get ahead. $200/year

Prescription Digital Therapeutics

All Newsletters
    196 articles
  • First
  • Previous
    • 1 of 20
  • Next
  • Last
Facebook’s RCT for AI bot Zenny. More trials
1.26.24
7 min. Read
FDA de novo for Google smartphone thermometer.
1.05.24
6 min. Read
PDT-to-virtual-clinic trend continues. HCPCS tweaks.
12.15.23
8 min. Read
Mahana Tinnitus. New CPT hopefuls. Better cuts salaries
12.01.23
6 min. Read
CMS weighs HCPCS for Natural Cycles, Leva, and Tyto. Plus: Akili Q3 results.
11.16.23
8 min. Read
metaMe Health seeks buyer by year-end. CMS offers up digital therapeutics nothingburger
11.06.23
6 min. Read
PDT Pipeline changes. Kinsa shuts down. Trials
10.27.23
5 min. Read
CPT decisions. Trials: Big Health, Mahana and more
10.20.23
6 min. Read
Akili CEO steps down. Aetna rolls back some virtual care coverage
10.06.23
5 min. Read
Biogen cuts digital, MedRhythms, Apple. Pfizer on PDTs.
9.29.23
6 min. Read
  • First
  • Previous
    • 1 of 20
  • Next
  • Last